Caribou Biosciences(CRBU) - 2025 Q4 - Annual Report

Clinical Development and Product Candidates - The company is advancing two clinical-stage allogeneic CAR-T cell therapy product candidates, vispa-cel and CB-011, targeting CD19 and BCMA respectively, with the goal of improving patient access and reducing manufacturing costs[30][31]. - Vispa-cel has received RMAT, Fast Track, and Orphan Drug designations from the FDA for relapsed or refractory large B cell lymphoma, while CB-011 has received Fast Track and Orphan Drug designations for relapsed or refractory multiple myeloma[30][31][40]. - The company has discontinued its GALLOP phase 1 trial of vispa-cel for lupus and the AMpLify phase 1 trial of CB-012 for acute myeloid leukemia, reallocating resources to its prioritized product candidates[32]. - The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapies for treating patients with hematologic malignancies[53]. - The company plans to conduct a pivotal phase 3 clinical trial of vispa-cel in approximately 250 2L LBCL CD19-naïve patients, targeting a population where about 60% of the 12,000 annual 2L LBCL patients in the U.S. are ineligible for autologous stem cell transplant[78]. - In the ongoing CaMMouflage phase 1 trial for CB-011, 48 patients were enrolled in the dose escalation portion, with the selected recommended dose for expansion being 450x10 viable CAR-T cells[87]. - The company is preparing and submitting a biologics license application (BLA) to the FDA, which includes detailed information on manufacturing and composition of product candidates[127]. - The FDA requires satisfactory completion of inspections of manufacturing facilities to ensure compliance with current Good Manufacturing Practices (cGMP) before approving a BLA[139]. Manufacturing and Technology - Allogeneic CAR-T cell therapies manufactured using the company's chRDNA technology can be produced in advance, allowing for rapid patient treatment and broader access, as only 25% of patients currently receive autologous CAR-T therapies[35]. - The manufacturing process for allogeneic CAR-T therapies is designed to be more efficient, with a smaller footprint and significantly lower costs compared to autologous therapies, allowing for scalability[34][35]. - The chRDNA technology allows for multiplex genome editing while maintaining genomic integrity, resulting in significantly lower levels of off-target edits compared to first-generation CRISPR-Cas9[35][36]. - The chRDNA technology allows for immune cloaking of CAR-T cells by removing endogenous HLA class I antigens and overexpressing HLA-E to reduce immune-mediated rejection[52]. - The manufacturing process for allogeneic CAR-T therapies can produce approximately 200-300 doses of vispa-cel and 50-100 doses of CB-011 from one manufacturing run[117]. - The company has made significant investments in process development to optimize and control product candidate characteristics and improve supply capabilities[118]. - The company utilizes multiple Contract Manufacturing Organizations (CMOs) for the production of critical materials, ensuring compliance with current Good Manufacturing Practices (cGMP)[120]. - The company’s chRDNA genome-editing technology does not rely on lentiviral or retroviral methods, reducing the risk of genomic mutagenesis[120]. Financial Performance and Funding - For the years ended December 31, 2025, and 2024, the company incurred net losses of $148.1 million and $149.1 million, respectively, with an accumulated deficit of $596.5 million as of December 31, 2025[203]. - The company has not commercialized any products and has never generated any revenue from product sales, focusing almost all financial resources on research and development[203]. - The company expects to incur significant expenses and operating losses over the next several years as it advances product candidates through clinical development and seeks regulatory approval[204]. - As of December 31, 2025, the company had cash, cash equivalents, and marketable securities of $142.8 million, which is expected to fund operations for at least the next 12 months[207]. - The company anticipates substantial additional financing will be needed to conduct its planned pivotal clinical trial for vispa-cel and to implement its operating plans[206]. - Future capital requirements may increase significantly due to costs associated with clinical trials, regulatory approvals, and expansion of workforce and facilities[208]. - The company has not generated any revenues from product sales and does not expect to do so for many years, if ever[215]. Regulatory Environment - The regulatory framework for the company’s product candidates is extensive, requiring substantial time and financial resources for compliance[121]. - The company must complete several steps, including nonclinical studies and IND applications, before initiating human clinical trials for its biologics[123]. - Clinical trials are conducted in three phases, with Phase 3 trials requiring two adequate and well-controlled studies to demonstrate safety and efficacy[131]. - The FDA has 60 calendar days to conduct an initial review of a BLA to determine if it is acceptable for filing[142]. - The FDA aims to complete its initial review of a standard application within 10 months and a priority review within 6 months from the filing date[142]. - The FDA may refer the BLA to an advisory committee for review, especially for applications presenting difficult safety or efficacy questions[143]. - The FDA may require post-approval studies, including phase 4 clinical trials, and impose risk management mechanisms to ensure product safety[145]. - Current product candidates have been designated as fast track products, allowing for greater interactions with the FDA and potential rolling reviews[147]. - Breakthrough therapy designations may be granted if preliminary clinical evidence shows substantial improvement over existing therapies[148]. - Priority review designation can shorten the FDA's review timeline from 10 months to six months for applications that significantly improve safety or effectiveness[149]. - RMAT designations provide benefits such as early interactions with the FDA and eligibility for accelerated approval based on surrogate endpoints[150]. - Accelerated approval may be granted for products that show meaningful therapeutic advantages based on surrogate endpoints[151]. - Pediatric studies are required for certain product candidates, and the FDA must agree on a pediatric study plan before submission of the BLA[163]. Challenges and Risks - The company faces competition from multiple biotechnology firms and larger pharmaceutical companies with greater resources in the cell therapy and genome editing fields[113]. - The company may face significant delays in clinical trials due to unforeseen events or regulatory requirements, which could materially harm its business[218]. - The company must submit an IND application to the FDA to initiate clinical trials, and any delays in this process could impact the timeline for product development[219]. - No other products using the chRDNA technology have advanced to clinical trials or received marketing approval in the U.S., indicating a high risk of failure in product development[220]. - The outcome of clinical trials is inherently uncertain, and negative results could significantly impact the company's business[221]. - There is a risk of serious adverse events (SAEs) associated with the allogeneic CAR-T cell therapies, including GvHD and other complications[222]. - Changes in manufacturing methods during clinical trials could affect product performance and may require additional testing and regulatory approvals, potentially delaying commercialization[227]. Employee and Organizational Structure - As of February 27, 2026, the company had 97 total employees, all of whom were full-time, with no representation by labor unions[190]. - The company has implemented a comprehensive talent strategy, including market-aligned salaries, performance-based incentives, and employee development programs[191]. - The company has incurred workforce reductions in July 2024 and April 2025, which may have negatively impacted employee relations[190]. - The company has established Environment, Health, and Safety initiatives to maintain a safe and healthy workplace[199].